Lilly Pays Up To $2.5bn For Scorpion, Will Put Big Pharma Muscle Behind PI3Kα Inhibitor

Deal Further Builds Out Breast Cancer Portfolio

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.